Articles citing this paper

Dr. Christie Hunter is the Chief Scientist, Application Development at SCIEX. Christie is focused on developing innovative MS workflows for the quantitative analysis of proteins and peptides, working in the SCIEX R&D department, and working collaboratively with researchers in the field. Over the years, she has developed workflows for MRM analysis of peptides, advanced data independent acquisition strategies, and most recently, ultra-high throughput quantification workflows for peptides/proteins using Acoustic Ejection Mass Spectrometry. Christie received her PhD in protein biochemistry from the University of British Columbia (Canada).

Dr. Joanna Bons is a postdoctoral fellow in the laboratory of Dr. Birgit Schilling at the Buck Institute for Research on Aging. After an engineer degree in Biotechnology, she joined the team of Dr. Christine Carapito at the BioOrganic Mass Spectrometry Laboratory in Strasbourg, France, where she specialized in quantitative mass spectrometry-based proteomics method development (SRM, PRM, DIA) for proteome quantification and characterization. She received her PhD in Analytical Chemistry in 2019, and then joined Dr. Birgit Schilling s laboratory. She focuses on developing and optimizing innovative DIA and targeted strategies for deciphering proteome and PTM remodeling in various collaborative projects, spanning neurodegenerative diseases, cancer, and metabolism dysfunction and diseases.

Dr. Birgit Schilling works at the Buck Institute for Research on Aging in the San Francisco Bay Area since 2000 as Professor and Director of the Mass Spectrometry Technology Center, specifically focusing on data-independent acquisition technologies and large-scale proteome quantification. Dr. Schilling received her PhD in Germany, and then moved to the University of California San Francisco (UCSF) as postdoctoral fellow. Dr. Schilling is interested in translational research and research that may aim towards therapeutic interventions to improve human aging or age-related diseases, specifically osteoarthritis and cancer. Dr. Schilling uses modern proteomic technologies to investigate mechanisms of aging, senescence and cancer, and using this knowledge to develop biomarkers and targets for interventions.